There is an urgent need to explore new strategies for the identification of high-risk groups for liver cancer and for the screening of HCC patients, especially those with early-stage HCC, AFP-negative HCC, and micro-liver cancer in the subclinical stage [6]. The gene discussed is AFP; the disease is liver cancer.